IMVT
IMVT clinical trials: Immunovant, Inc.
Every trial on ClinicalTrials.gov where Immunovant, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 19
- Trials linked
- 19
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
IMVT on the catalyst calendar · IMVT registry changes
- Primary completion Dec 2027Sponsor estimatePhase 3NCT07039916Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia GravisImmunovant Sciences GmbH · Generalized Myasthenia GravisRecruitingIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2028Sponsor estimatePhase 2NCT07032662Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Immunovant Sciences GmbH · Chronic Inflammatory Demyelinating PolyneuropathyRecruitingIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2027Sponsor estimatePhase 2NCT07018323A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' DiseaseImmunovant Sciences GmbH · Graves' DiseaseRecruitingIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2030Sponsor estimatePhase 2NCT07286006A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)Immunovant Sciences GmbH · Graves' DiseaseEnrolling by invitationIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2028Sponsor estimatePhase 2NCT06979531Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease ActivityImmunovant Sciences GmbH · Primary Sjögren's SyndromeActive, not recruitingIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 10, 2025ActualPhase 3NCT05403541Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With...Immunovant Sciences GmbH · Generalized Myasthenia GravisTerminatedIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2026Sponsor estimatePhase 2NCT06980805A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)Immunovant Sciences GmbH · Subacute Cutaneous Lupus ErythematosusActive, not recruitingIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2028Sponsor estimatePhase 2NCT06727604A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' DiseaseImmunovant Sciences GmbH · Graves' DiseaseRecruitingIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 16, 2026ActualPhase 2NCT07188844An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Immunovant Sciences GmbH · Chronic Inflammatory Demyelinating PolyneuropathyTerminatedIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 20, 2026ActualPhase 2NCT05581199To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDPImmunovant Sciences GmbH · Chronic Inflammatory Demyelinating PolyneuropathyTerminatedIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 25, 2025ActualPhase 2NCT05907668A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' DiseaseImmunovant Sciences GmbH · Graves DiseaseCompletedIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2, 2026ActualPhase 3NCT05517447Extension Study to Assess Batoclimab in Participants With Thyroid Eye DiseaseImmunovant Sciences GmbH · Thyroid Eye DiseaseTerminatedIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 2NCT06754462A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid...Immunovant Sciences GmbH · Rheumatoid ArthritisActive, not recruitingIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 3, 2026ActualPhase 3NCT05524571Study to Assess Batoclimab in Participants With Active Thyroid Eye DiseaseImmunovant Sciences GmbH · Thyroid Eye DiseaseCompletedIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2, 2025ActualPhase 3NCT05517421Study to Assess Batoclimab in Participants With Active Thyroid Eye DiseaseImmunovant Sciences GmbH · Thyroid Eye DiseaseCompletedIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 7, 2020ActualPhase 2NCT03863080A Study of RVT-1401 in Myasthenia Gravis (MG) PatientsImmunovant Sciences GmbH · Myasthenia GravisCompletedIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2, 2021ActualPhase 2NCT03938545ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )Immunovant Sciences GmbH · Graves' Ophthalmopathy (GO)TerminatedIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 1, 2021ActualPhase 2NCT04253236To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).Immunovant Sciences GmbH · Warm Autoimmune Hemolytic AnemiaTerminatedIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 29, 2020ActualPhase 2NCT03922321Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)Immunovant Sciences GmbH · Graves' OphthalmopathyCompletedIMVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 19 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner